Eligibility is mutation-specific and drug-label-specific. Do not infer it from a nearby exon number; have the neuromuscular/genetics team document amenability and confirm current regulatory status.
What this means in real life
Exon-skipping medicines are designed for particular mutations. In the United States, approved products target mutations amenable to skipping exon 45, 51 or 53. “Amenable” means that skipping that exon is expected to restore the reading frame for the person’s exact mutation; it does not mean everyone with a deletion involving or near that exon qualifies.
Eligibility must be matched against the current FDA label and the original genetic report. For example, two people may both have a report mentioning exon 51 but have different deletions, only one of which may be amenable to exon 51 skipping. These medicines received accelerated approval based on increased dystrophin, and confirmatory studies are used to verify clinical benefit. Families should discuss the strength of evidence, infusion burden, monitoring, insurance requirements and alternatives—not only mutation eligibility.
Do not change another treatment or delay standard cardiac, respiratory, rehabilitation and steroid care while pursuing mutation-specific therapy. The clinic should document the exact mutation-to-drug match in writing and review the current prescribing information.
A practical checklist
- ✓
Use the original genetic report, not a family summary or screenshot.
- ✓
Have genetics or the neuromuscular prescriber document amenability in writing.
- ✓
Check the current FDA label, age requirements and contraindications.
- ✓
Ask what monitoring and infusion schedule the specific medicine requires.
- ✓
Request a coverage plan and appeal strategy before assuming approval.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- Which exact deletion or variant makes this mutation amenable?
- Is the proposed use within the current FDA indication?
- What clinical benefit is known, and what remains uncertain?
- How will response and side effects be monitored?
- What are the practical and financial burdens compared with other options?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.